NSGO-OV-UMB1/ENGOT-OV30: A phase II study of durvalumab in combination with the anti-CD73 monoclonal antibody Oleclumab in patients with relapsed ovarian cancer
2024; Elsevier BV; Volume: 188; Linguagem: Inglês
10.1016/j.ygyno.2024.06.017
ISSN1095-6859
AutoresM.R. Mirza, Luka Tandarić, J R Henriksen, Juhani Mäenpää, René dePont Christensen, Marianne Waldstrøm, K Lindemann, Henrik Roed, Annika Auranen, L A Akslen, Liv Cecilie Vestrheim Thomsen, soeren Lindberg, Kristine S. Madsen, Line Bjørge,
Tópico(s)Immune cells in cancer
ResumoIn patients with epithelial ovarian cancer (EOC), the clinical efficacy of monotherapy with immune checkpoint inhibitors (ICIs) against PD-1/PD-L1 is modest. To enhance response rates to these immunotherapeutic agents and broaden the indications for their use, new approaches involving combinational therapy are needed. The immune regulator CD73 is a potential target, as it promotes tumor escape by producing immunosuppressive extracellular adenosine in the tumor microenvironment. Here, we present the results from the NSGO-OV-UMB1/ENGOT-OV-30 trial evaluating the activity of combining the anti-CD73 antibody oleclumab with the anti-PD-L1 checkpoint inhibitor durvalumab in patients with recurrent EOC.
Referência(s)